Open AccessDetermination of HER-2 status on FNAC material from breast carcinomas usingin situhybridization with dual chromogen visualization with silver enhancement (dual SISH)
Author(s) -
Elsa Beraki,
Torill Sauer
Publication year - 2010
Publication title -
cyto journal/cytojournal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.371
H-Index - 27
eISSN - 0974-5963
pISSN - 1742-6413
DOI - 10.4103/1742-6413.70968
Subject(s) - polysomy , visualization , pathology , in situ hybridization , dual (grammatical number) , audio visual , dual purpose , in situ , histology , medicine , biology , computer science , chemistry , artificial intelligence , art , mechanical engineering , biochemistry , gene expression , multimedia , literature , organic chemistry , gene , engineering
During the last years, HER-2 status kits and protocols for chromogen visualization of hybridization signals have come on the market. The first generation using chromogen visualization used single color probes. The second generation, now emerging on the market, uses dual chromogen visualization. The aim of this study has been to test a new dual color chromogen kit (Ventana INFORM HER2 Dual Colour ISH Roche ® ) and compare the results with our in-house method(s). The material consisted primarily of cytological material from invasive breast carcinomas in 49 women. Dual SISH was done on all 49 cytological and histological specimens. The histological specimens were treated according to the manufacturer’s recommendations. The procedure was modified in several steps in order to adapt it to the cytological material. Hybridization failed in two cytological specimens. Dual SISH showed concordant results on cytological and histological material as to amplified/not amplified. The included cases had the same HER-2 expression in the invasive and the in situ components on histology. Four IDC showed HER-2 amplification (8.5%). Polysomy was found in two cases. All dual SISH results except for one concurred with the results of the in-house method(s) (1/47=2.1%). The dual SISH is suitable for cytological examination of HER-2 status. The protocol must be optimized for cytological material.